Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ev3, FoxHollow Merger Creates Peripheral Vascular Leviathan

This article was originally published in The Gray Sheet

Executive Summary

Endovascular device makers ev3 and FoxHollow are combining their respective strong European and U.S. sales forces in a merger announced July 22

You may also be interested in...



FoxHollow Integration Problems Plague ev3 In First Quarter

Endovascular device firm ev3's failure to meet first-quarter 2008 revenue targets is being blamed on unexpected challenges in assimilating the FoxHollow Technologies sales force

FoxHollow Integration Problems Plague ev3 In First Quarter

Endovascular device firm ev3's failure to meet first-quarter 2008 revenue targets is being blamed on unexpected challenges in assimilating the FoxHollow Technologies sales force

People In Brief

Edwards Lifesciences restructuring: Cardiovascular technology firm announces planned mid-year departures of corporate VPs Anita B. Bessler, Stuart L. Foster and Alex Martin, along with "strengthened alignment" into a business-unit organizational structure. Corporate VPs Donald E. Bobo, Paul C. Redmond, Carlyn D. Solomon and Larry L. Wood will take on additional U.S. sales, marketing and operational duties in their units, reporting to CEO Michael A. Mussallem. Bessler and Foster will continue in advisory roles with the company

Related Content

UsernamePublicRestriction

Register

MT025070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel